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Lycopene has been proposed to protect against prostate cancer through various properties including decreased lipid oxidation,
inhibition of cancer cell proliferation, and most notably potent antioxidant properties. Epidemiologic studies on the association
between lycopene and prostate cancer incidence have yielded mixed results. Detection of an association has been complicated by
unique epidemiologic considerations including the measurement of lycopene and its major source in the diet, tomato products,
and assessment of prostate cancer incidence and progression. Understanding this association has been further challenging in
the prostate-speciﬁc antigen (PSA) screening era. PSA screening has increased the detection of prostate cancer, including a
variety of relatively indolent cancers. This paper examines the lycopene and prostate cancer association in light of epidemiologic
methodologic issues with particular emphasis on the eﬀect of PSA screening on this association.
1.Introduction
Several chemoprotective properties of lycopene on prostate
cancer have been proposed, including potent antioxidant
properties,decreasedlipidoxidation,inhibitionofcancerous
cell proliferation at the G0-G1 cell cycle transition, and pro-
tection of lipoproteins and DNA [1, 2]. These mechanistic
studies have stimulated the examination of lycopene and its
primary source, tomato products, on risk of prostate cancer.
However,studiesonlycopeneandtomatointakeandprostate
cancer incidence have yielded mixed results. The study of
this relationship has been complicated by unique and chal-
lenging epidemiologic considerations in the measurement of
lycopene and on the inﬂuence of prostate-speciﬁc antigen
(PSA) screening on prostate cancer incidence and progres-
sion. As with all epidemiologic studies, validity depends on
the quality of the methodology. This paper brieﬂy describes
the methodology essential for conducting studies on the
association between lycopene and prostate cancer incidence
and provides an updated review of studies of lycopene and
tomato products with prostate cancer risk.
2. Measurement of Lycopene and
Tomato Products
Lycopene is a carotenoid devoid of vitamin A activity. The
major source by far, particularly in Western populations,
is tomato and tomato products; a few other foods such as
watermelons and pink grapefruit also contain lycopene. In
epidemiologic studies, approaches to assess an individual’s
lycopene intake or status include studies that estimate intake
of lycopene (based on reported intake of foods and food
content of lycopene from food composition databases),
studies that assess tomato product intake as a surrogate of
lycopene intake, and studies that measure lycopene levels in
theserumorplasma.Anissuethatisnotuniqueforlycopene,
but perhaps of special importance for this carotenoid, is
the variable absorption of lycopene from diﬀerent food
sources.Inparticular,cookinginanoilmediumsubstantially
enhances bioavailability of lycopene in the intestine because
lycopene is highly bound to plant source matrices and is
highly lipophilic. The measure of lycopene in the serum
has theoretical advantages of accounting for absorption and2 Journal of Oncology
not relying on study participants’ food recall and accuracy
of food composition tables. On the other hand, serum
studies have frequently relied on a single measure, and how
well a single measurement reﬂects long-term intake is not
entirelyclear.Also,sincelycopenecomeslargelyfromtomato
sources, circulating lycopene level may be acting as a sur-
rogate of tomato product intake, and other components of
tomatoes may account for any observed association with
cancer risk. Finally, a population that consumes overall
low levels of lycopene or similar levels of lycopene across
individuals may result in insuﬃcient contrast between high
and low consumers.
3. The Inﬂuence of PSAScreeningon
ClinicalandEpidemiologic Aspects of
ProstateCancer Incidence
PSA release into the serum occurs with tissue breakdown
between the prostate gland lumen and capillaries. The origi-
nalpurposeofthePSAmeasurementwastomonitorprostate
cancer progression and recurrence. The Food and Drug
Administration approved PSA testing for monitoring disease
status in men with prostate cancer in 1987 and expanded
its use to diagnosing prostate cancer in 1992. This approval
was followed by professional society guidelines that sup-
ported the use of PSA testing for prostate cancer screening.
Consequently, PSA became widely used as a screening test
in the United States and increasingly in other countries.
As a screening modality, the sensitivity and speciﬁcity of
PSA varies based on the cut-oﬀ.F o re x a m p l e ,aP S Al e v e l
of 3ng/mL has a sensitivity of 32% for detecting any
prostate cancer and 68% for high-grade prostate cancer and
a speciﬁcity of 85%. If this level were increased to 4ng/mL
the sensitivity would decrease to 21% for any prostate cancer
and 51% for high grade prostate cancer but speciﬁcity would
improve to 91% [3].
Elevated serum PSA may precede invasive carcinoma
by a minimum of 5–10 years. Thus, PSA testing enabled
earlier detection of prostate cancer. The rate of ﬁrst-time
PSA testing was strongly correlated with prostate cancer
incidence rates. With the onset of PSA for screening, prostate
cancer incidence increased and peaked in 1992 and declined
thereafter [4]. Localized, nonmetastatic cancers accounted
for most of the increased incidence. Prior to widespread
PSA use for screening, prostate cancer diagnosis was largely
prompted by physical exam ﬁndings of an enlarged prostate
or symptoms ranging from urinary incontinence to more
advanced spinal cord compression and bony pain from
metastasis; therefore, prostate cancer was mostly detected
in relatively advanced stages. Invasive carcinoma prevalence
increases with age: 2% for men in their 30s compared with
64% for men in their 70s [5]. One-third of men under age 80
will have prostate cancer detected on autopsy. The lifetime
risk of prostate cancer is 16% while the risk of mortality
from prostate cancer is 2.9% [6]. Thus a “PSA screening
era” beginning in 1988, FDA approved in 1992, and peaking
between 1992 and 1998 has been referred to as a period
in which prostate cancers diagnosed by serum PSA alone
encompassedavarietyofstagesofprostatecancers,including
clinically indolent cancers [4, 7].
PSA testing revolutionized the detection of prostate
cancer but was not without unexpected consequences. In
addition to diagnosing biologically indolent cancers, PSA
elevation occurs with benign conditions including benign
prostatic hypertrophy, prostatitis, subclinical inﬂammation,
ejaculation, digital rectal exams (potentially performed just
prior to patients having their PSA lab drawn), perineal
trauma, prostatic infarction, urinary retention, biopsy, and
transurethral resection of the prostate. The number of false
positives is high, leading to numerous negative biopsies.
The inﬂuence of PSA on prostate cancer mortality has
been controversial, with randomized trials not yielding a
clear answer. However, undoubtedly PSA screening has
caused an increase in the number of indolent cancers being
treatedaggressivelyandultimatelyledtoincreasedmorbidity
from side eﬀects of treatment. The majority of newly
diagnosed prostate cancers were clinically localized and
unlikely clinically signiﬁcant to involve aggressive medical
and surgical therapy such as radical prostatectomy with
radiation ablation intended to cure early-stage cancers. For
these reasons, in 2011 the United States Preventive Services
Task Force recommended against PSA screening for prostate
cancer regardless of age, race/ethnicity, and family history.
Beyond the clinical consequences, PSA screening has
altered the landscape of prostate cancer epidemiology. Many
more cancers are diagnosed, including a substantial propor-
tion of relatively indolent cancers, and the cancers are diag-
nosed earlier in their natural history, often before evidence
of aggressive behavior is manifested. Thus, depending on at
what stage and on what subtype of prostate cancer a risk
factor may be acting, the relationship between this risk factor
andprostatecancerriskmaydiﬀerinpopulationsexposedor
not exposed to widespread PSA screening [8]. By increasing
the heterogeneity in prostate cancers being diagnosed, PSA
screening has added complexity to the epidemiologic study
of prostate cancer.
4. Epidemiologic Studies
4.1. Clinical Trials. A number of randomized clinical trials
haveexaminedlycopeneandprostatecancerprogressionand
mortality in men diagnosed with prostate cancer [9]. The
randomized studies have been small and inconclusive [10].
In a double-blind randomized placebo-controlled trial, 105
African American male veterans recommended for biopsy
to detect prostate cancer were administered tomato sauce
containing 30mg/day of lycopene or placebo over 21 days
[11]. PSA and lycopene levels were measured, and the group
randomized to lycopene had an increase in serum lycopene
and decrease in PSA while the placebo group had the reverse,
with a decrease in serum lycopene and increase in PSA. This
study did not report a signiﬁcant decrease in prostate cancer
risk for individuals administered lycopene, but the study
duration of 21 days was likely inadequate to signiﬁcantly
inﬂuence prostate cancer risk.
Two other studies examined PSA levels in relation to
lycopene administration [12]. One study reported a declineJournal of Oncology 3
inPSAinthelycopeneaswellasplacebogroupafter1month
of intervention but return to baseline PSA levels for both
groups after 4 months of followup [10]. Schwartz et al. [12]
did not report a decrease in PSA levels among individuals
administered lycopene. In general, the clinical trials have
been considerably limited by size, length of study duration,
and other methodological issues and do not provide strong
support or refutation of an association between lycopene
and prostate cancer risk. No adequately sized randomized
studies of lycopene for prostate cancer prevention have been
conducted.
4.2. Prospective Dietary Studies. Prospective and nested case
control studies have been published previously in qualitative
[13, 14] and quantitative reviews [15]. In a meta-analysis of
prospective studies up to 2003 [15], high intake of raw but
not cooked tomatoes was associated with a decreased risk
of prostate cancer (relative risk (RR) 0.71, 95% conﬁdence
interval (CI): 0.57–0.87). Subsequent cohort studies on
dietary lycopene intake [16, 17] have not reported signiﬁcant
inverse associations with prostate cancer risk. However, these
studies were conducted in the post-PSA era that likely
encompassed a heterogeneous group of prostate cancers that
included latent and incident cancers.
Among prospective dietary studies, four [18–21]o fs i x
cohorts report an inverse relationship between lycopene or
tomato consumption and prostate cancer incidence. The
largest and only study with multiple assessments of diet
was conducted in the Health Professionals Follow-up Study
(HPFS) [18, 19]. The HPFS ﬁrst reported an inverse associ-
ation between lycopene intake in 1986 with prostate cancer
diagnosed between 1986 and 1992: RR for high versus low
quintile of intake = 0.79 (95% CI: 0.64–0.99, Ptrend = 0.04)
[18]. High intake of tomato-based products was associated
with a 35% decreased risk of total prostate cancer (RR 0.65,
95%CI:0.44–0.95)and53%decreasedriskofadvancedstage
prostate cancer (RR 0.47, 95% CI: 0.22–1.00; Ptrend = 0.03).
The HPFS analysis was updated for prostate cancer cases
between 1992 and 1998 using cumulative average updated
intakes (i.e., averaging intake from all the dietary question-
naires up to the time period of risk) of lycopene from 1986
to 1998 with a similar inverse association detected: RR = 0.83
(95% CI: 0.70–0.98, Ptrend = 0.02) [19]. The HPFS assessed
dietary intake every four years, and the timing of intake in
relation to period of risk for prostate cancer was assessed.
When baseline lycopene intake in 1986 was evaluated for
prostate cancer cases during the entire follow-up period,
no signiﬁcant association was seen. However, statistically
signiﬁcant inverse associations were found when using the
questionnaire closest in time to the time period of risk
(RR for high versus low lycopene intake = 0.84, 95% CI:
0.74–0.96, Ptrend = 0.02) and cumulative average updated
lycopene intake (RR for high versus low lycopene intake =
0.84, 95% CI: 0.73–0.96, Ptrend = 0.003). These ﬁndings
suggest that lycopene may be acting relatively late in the
carcinogenic process. Alternatively, a single measurement of
dietary intake at baseline may not be the best measurement
toreﬂectthepotential impactof lycopenein altering prostate
carcinogenesis, compared with multiple updated dietary
measurements. Individual tomato products were examined
in relation to prostate cancer risk, and the strength of the
associationcorrespondedtoassociationofthefooditemwith
serum lycopene levels, which were concurrently available in
the HFPS. For example, tomato sauce, the most bioavailable
form of lycopene, was most strongly related to decreased
prostate cancer risk (RR for ≥2 servings/week versus <1
serving/month = 0.77, 95% CI: 0.66–0.90), followed by
tomato and pizza but not tomato juice. There was an even
stronger association for advanced prostate cancer: RR for ≥2
servings/week versus <1 serving/month of tomato sauce =
0.65 (95% CI: 0.42–0.99, Ptrend = 0.02).
A similar magnitude decrease in prostate cancer was
reported in the California Seventh Day Adventist cohort
between 1974 and 1982 for men with high tomato consump-
tion [21]. High intake of tomatoes was associated with a
statistically signiﬁcant 40% decreased risk of prostate cancer
(RR 0.60, 95% CI: 0.37–0.97). In another study, a 50% lower
risk of prostate cancer was reported for high compared with
lowtomatoconsumptioninUSmenbetween1987and1990:
RR 0.50 (95% CI: 0.30–0.90, Ptrend = 0.03), but few details
were provided [20].
Dietary cohort studies that did not report associations
withprostatecancerincidencefrequentlyhadlowerlycopene
and tomato intake compared with studies that report an
association. A dietary cohort study based in The Netherlands
between 1986 to 1992 did not report an association between
tomato intake and prostate cancer incidence [22]. While this
cohort took place between the same time period as the initial
HPFS analysis, tomato consumption was low compared
with the HPFS. In addition, consumption of tomato-based
products, which contain more bioavailable lycopene, was not
speciﬁcally addressed.
A diet-based cohort study of individuals in the Prostate,
Lung,Colorectal,andOvarianScreeningTrial[17]examined
intakes of lycopene and top food sources of lycopene but did
not ﬁnd inverse associations for lycopene, raw tomatoes,
canned tomatoes, or other processed tomato products
(ketchup, tomato sauce, pizza, lasagna, tomato and vegetable
juice, chili) with total or nonadvanced prostate cases. Pre-
dominately white men (90.7%) enrolled in this study
between 1993 and 2001 received baseline PSA screening or
digital rectal examination and completed annual question-
naires. Men with a PSA level >4ng/mL or digital rectal
examination concerning for prostate cancer were referred to
their medical provider for further diagnostic evaluation and
staging of prostate cancer. The majority (92%) of prostate
cancers were conﬁrmed for stage and grade. Nonadvanced
disease (Gleason score <7 or stage I or II) comprised 61%
of total prostate cancer cases and was not associated with
total lycopene intake or lycopene from processed foods.
Greater consumption of spaghetti/tomato sauce and pizza
was associated with decreased incidence of advanced disease
but did not reach statistical signiﬁcance (RR 0.81, 95% CI:
0.57–1.16 and RR 0.79, 95% CI: 0.56–1.10, respectively).
The association of tomato products with advanced but not
nonadvanced prostate cancer suggests a possible stronger
role for lycopene in advanced disease. Limitations of this4 Journal of Oncology
study include the assessment of lycopene intake from a single
baseline measurement. In addition, intake for all but raw
tomatoes was low in this population, with no more than two
servings per week (mean total lycopene intake 11,511 and
standard deviation 8,498μg/d). Further, a large portion of
prostate cancer cases were diagnosed by initial PSA screen-
ing, and total prostate cancers reﬂected a heterogeneous mix
of mostly nonadvanced prostate cancer cases.
Dietary lycopene was not reported to have an association
with prostate cancer risk in a prospective study from the
Prostate Cancer Prevention Trial [16]. The PCPT originated
as a randomized trial of ﬁnasteride but was converted to
a prospective observational study. Diet was assessed one
year after randomization in 1994. Men underwent annual
screening for prostate cancer using digital rectal examination
and PSA. Men with an abnormal digital rectal examination
or PSA level 4ng/mL or greater were encouraged to receive
a prostate biopsy. At the ﬁnal study year all men not
previously diagnosed with prostate cancer were oﬀered
prostate biopsies. This resulted in the inclusion of incidental
cases of prostate cancer that contributed to the substantial
24.8% of prostate cancer cases diagnosed in men originally
randomized to the control group. The majority of cancers
were localized and detected by screening or incidentally
discovered, and it is possible that low-grade cancers have
diﬀerent characteristics from high-grade cancers. Prior
studies of lycopene intake have suggested stronger inverse
associations with advanced prostate cancer [18]. In addition,
it may be necessary to assess lycopene through simple
updated or cumulative average updated intakes rather than
a single baseline measurement.
4.3. Prospective Serum and Plasma Studies. An u m b e ro f
studies have examined serum or plasma lycopene from bio-
banks in relation to subsequent prostate cancer risk. The
studies were typically nested case control in design; incident
cases and matched cancer-free controls over the follow-up
period were identiﬁed, and serum or plasma lycopene was
measured in the banked biospecimens. In a meta-analysis of
prospective studies up to 2003 [15], high serum lycopene
levels were associated with signiﬁcant decreased risk of
prostate cancer: RR = 0.78 (95% CI: 0.61–1.00). Subsequent
studies on serum lycopene levels conducted in the post-PSA
era[23–28]havenotreportedsigniﬁcantinverseassociations
with total prostate cancer risk.
Oneoftheearlieststudiestoreportaninverseassociation
between serum lycopene and prostate cancer risk was a
nested case control study of 103 prostate cancer cases
matched with 103 controls among 25,802 male residents of
Washington County, MD who donated blood in 1974 [29].
A nonsigniﬁcant 50% reduction in prostate cancer risk was
reported (OR 0.50; 95% CI: 0.20–1.29). Two of the largest
nested case control studies reported inverse associations
between plasma lycopene and prostate cancer risk [30, 31].
Plasma lycopene levels were higher in these multicentered
US cohorts compared with other studies, which may reﬂect
the higher education level in these populations. A nested
case control study within the Physicians’ Health Study,
a randomized, placebo-controlled trial of aspirin and β-
carotene, assessed incident prostate cancer cases in 578
men compared with 1294 age- and smoking-status-matched
controls [30]. Plasma lycopene was lower in cases than
controls. Men with higher plasma lycopene had a borderline
signiﬁcant decreased risk of prostate cancer (highest quintile
RR = 0.75; 95% CI: 0.54–1.06; Ptrend = 0.05). There was
a signiﬁcantly greater decreased risk for aggressive (high
stage or high grade) prostate cancer: highest quintile plasma
lycopene,RR=0.56(95%CI:0.34–0.91;Ptrend = 0.05).These
associations were not confounded by covariates includ-
ing age, smoking status, body mass index, physical activity,
alcohol intake, multivitamin use, or plasma total cholesterol
level.
In a nested case control study within the prospective
HPFScohort,450incidentcasesofprostatecancerdiagnosed
between 1993 and 1998 were matched with 450 controls by
age, time, month, season, and year of blood donation [31].
A nonsigniﬁcant inverse association was reported for plasma
lycopene and risk of prostate cancer: RR for highest versus
lowest quintile, 0.66 (95% CI: 0.38–1.13). This association
was statistically signiﬁcant for men older than 65 years
at time of plasma donation: RR for highest versus lowest
quintile, 0.47 (95% CI: 0.23–0.98), but was not observed for
younger men.
Serum lycopene was recently assessed in a nested case
control study within the Prostate Cancer Prevention Trial
(PCPT) [28]. There was no association between serum ly-
copene and prostate cancer incidence, but incidentally diag-
nosed prostate cancer cases by end-of-study biopsies were
analyzed alongside prostate cases diagnosed by screening.
In a reanalysis that included only cancers diagnosed from
abnormal screening there was a signiﬁcant inverse associa-
tion between high serum lycopene and prostate cancer [7].
The cancers assessed by end-of-study biopsy were relatively
static (e.g., no PSA elevation or sign of clinical progression)
during the study period, so may not be appropriately
considered as “incident” prostate cancer.
Several other serum lycopene studies reported nonsignif-
icant inverse associations [23–25, 27] or no association [26,
32] with prostate cancer risk. However, these studies were
conducted in the post-PSA era that likely encompassed a
heterogeneous group of prostate cancers that included latent
and incident cancers. As with the PCPT, an association
with lycopene could be missed. In the large European
study (EPIC) by Key et al., a statistically signiﬁcant inverse
association was observed for cases diagnosed at an advanced
stage [26]. In this study, men in the highest versus lowest
quintile of lycopene level had a RR of 0.40 (95% CI: 0.19–
0.88).
4.4. Case Control Dietary Studies. Several studies retrospec-
tively examined the association between tomatoes, tomato-
based products or lycopene, and prostate cancer risk, with
mixed results. In a meta-analysis of case control studies
through 2003 [15], high intakes of raw tomatoes, cooked
tomatoes, and lycopene were not associated with decreased
prostate cancer risk.Journal of Oncology 5
A strong inverse dose-response relationship between
lycopene intake and histopathologically conﬁrmed prostate
adenocarcinoma risk was reported in a case control study
of Chinese men [33]. Lycopene intake was assessed using
a reproducible and validated 130-item food frequency
questionnaire for elderly men in China [34]. For lycopene
intakesof1609–3081,3081–4917,and>4917μg/d,theRRsof
prostate cancer compared with lycopene intake <1609μg/d
were0.47(95%CI:0.25–0.86),0.40(95%CI:0.21–0.77),and
0.17 (95% CI: 0.08–0.39), respectively. The RRs reported for
lycopene and prostate cancer in this study were stronger than
some prior studies. This study also examined green tea and
vegetable and fruit intake and reported strong, signiﬁcant
inverse associations for all these associations. The incidence
of prostate cancer is lower in developing countries such as
China, compared with Western countries. In China PSA
screening is not as commonly widely used compared with
Western countries. Prostate cancer is thus usually diagnosed
at more advanced stages. While further information and
stratiﬁcation based on prostate cancer grade and staging
were not provided in this study, the lower prevalence of
PSA screening practices in China compared with the USA
suggests prostate cancer cases in this cohort were more likely
to be at advanced stages. The strong association between
lycopene and probable advanced prostate cancer suggests a
role for lycopene in inﬂuencing risk of aggressive cancer.
A signiﬁcant inverse association between tomato intake
and prostate cancer was similarly reported in a case control
study of 617 Canadian men with prostate cancer and 636
age-matched controls conducted between 1989 and 1993.
The RR of prostate cancer was 0.64 (95% CI: 0.45–0.91)
for tomato intake >73g/day compared with <24g/day. There
was no signiﬁcant association reported for lycopene intake
and prostate cancer [35].
In a case control study of 130 prostate cancer cases in Ira-
nian men, tomato consumption of greater than 100g/week
was nonsigniﬁcantly inversely associated with decreased
prostate cancer risk (RR 0.45; 95% CI: 0.09–2.12) [36]. Food
intake was assessed based on the past two months of intake,
and tomato intake questions included tomato extract and
dressing. However, it is unclear whether this tomato group
included both raw and processed tomatoes.
An additional study reported a nonsigniﬁcant inverse
associationbetweendietarylycopeneandprostatecancerrisk
[37] while several reported no association [38–40].
4.5. Case Control Serum and Plasma Studies. Three case
control studies of plasma lycopene reported strong inverse
associations with histopathologically conﬁrmed prostate
cancer [41–43]. One study of non-Hispanic Caucasian men
used high-pressure liquid chromatography (HPLC) to exam-
ine plasma lycopene isoforms [42]. An inverse association
was reported for cis-lycopene-1 only. cis-lycopenes 2 through
5 individually and in sum as total cis-lycopene and trans-
lycopene were not associated with prostate cancer risk. This
study suggests the structural type of lycopene measured may
inﬂuence the ability to detect an association, as one cis
isomer but not total cis-o rtrans-lycopene was associated
with decreased prostate cancer risk. Data on individual
structural lycopene isomers have been limited. However,
a study in the HPFS found that the isomers were highly
correlated with each other, making any speciﬁc eﬀects
diﬃcult to distinguish [44].
The multicentered case control Third National Health
and Nutrition Examination Survey (NHANES III) of U.S.
C a u c a s i a na n dA f r i c a nA m e r i c a nm e na g e d4 0 – 7 9y e a r s
reported a signiﬁcant inverse association between serum
lycopene and aggressive prostate cancer (highest com-
pared with lowest quartile RR = 0.37; 95% CI: 0.15–0.94;
Ptrend = 0.04) and nonsigniﬁcant association between serum
lycopene and prostate cancer (highest compared with lowest
quartile RR = 0.65; 95% CI: 0.36–1.15; Ptrend = 0.09) [45].
Caution should be used in interpreting results from case
control plasma or serum studies because the cancers could
possibly be inﬂuencing lycopene level, resulting in reverse
causation.
5. Lycopene andProstateCancer
Associations: Conclusions
This paper focused on prostate cancer incidence that may
or may not have been detected by initial PSA screening
and highlights diﬀerences in the association with lycopene
based on prostate cancers initially screened with PSA testing
compared with cancers diagnosed in more advanced stages.
Elevated PSA may be attributed to a number of benign
factors, including the highly prevalent benign prostatic
hypertrophy in older men, and should not be used in
isolation along with single serum measurements for the
diagnosis of prostate cancer. Randomized interventions of
lycopene and prostate cancer risk have been limited in scope,
and some used PSA as an endpoint [10, 11]. Thus, trials
do not provide strong support either for or against a causal
association.
The epidemiologic literature on lycopene intake or level
and prostate cancer based on observational studies has
been inconsistent overall. Earlier studies had appeared more
promising but some recent studies are not supportive.
There are several potential explanations for this pattern.
One potential explanation is that there was a relative over-
reporting and publishing of positive studies in the earlier
years, followed by a correction of this publication bias as the
hypothesis grew in interest and null studies were published.
If so, then it may be concluded that there is unlikely to
be a causal connection between lycopene intake and risk of
prostate cancer.
An alternative possibility is that the earlier studies were
conducted largely before the onset of PSA screening, where
diagnosis of prostate cancer usually implied a period of
increasingaggressivebehaviorleadingtothediagnosis.Thus,
the exposure was linked to the development of aggressive
behavior in cancers with biologic potential to progress. In
the PSA era, 1992–1998 with peak in 1992 following FDA
approval as a screening test for prostate cancer, the diagnosis
of prostate cancer is not typically linked to aggressive
behavior [4, 7]. An example of this phenomenon may be the
subgroup of cancers in the PCPT that were diagnosed at end6 Journal of Oncology
of study biopsy. There was a high prevalence of undiagnosed
prostate cancer, even among the youngest group of men in
the study (55–59 years), which suggests that most of the
cancers eventually diagnosed during the study period were
presentatbaseline.Throughoutthe7-yearfollowup,thecan-
cers diagnosed at end-of-study biopsy showed no evidence
of clinical or biochemical progression [28]. Prior studies
have shown that most cancers, even many with high-grade
Gleasonscores,donotprogressoverprolongedtime,anditis
well established that only a fraction of prostate cancers result
in the most advanced and clinically signiﬁcant stage and
mortality [46]. Thus, the majority of these cancers was likely
present at the onset of the study and may be considered static
cancers. In fact, when reanalyzed as a case-only study, higher
serum lycopene levels in the PCPT appeared to be inversely
associated preferentially with cancers that showed evidence
of progression relative to cancers that showed no indication
of progression. In modeling two patterns of prostate cancer
progression, one with low lycopene exposure and rapid
tumor growth that reaches a threshold PSA level for clinical
diagnosis and the second with high lycopene exposure and
slow progression, the latter may be diagnosed at a much later
time through an incidental random biopsy rather than PSA.
Thus, asymptomatic cancers diagnosed at the end-of-study
by biopsy may signify cancers that were inhibited rather than
incident cancer. Thus, a possible interpretation is that high
levels of lycopene may have inhibited some existing cancers
to undergo progression.
Some evidence supports the premise that PSA screening
and type of tumor endpoint are critical. For example, the
HPFS was analyzed before and after peak PSA testing in
the early 1990s. Before PSA testing (1986–1992) tomato
sauce intake was inversely associated with prostate cancer
incidence and stronger for advanced stage cancers. While
the association for total prostate cancer incidence was
attenuated during the PSA era (1992–1998), the association
with metastatic prostate cancer persisted. In addition, in the
large EPIC study [26] serum lycopene level was inversely
associatedwithriskofadvancedstageprostatecancerbutnot
nonadvanced prostate cancer.
Additional factors may contribute to the heterogeneity in
the literature. As discussed above, studies based on intake
are limited by the assessment of intake, food composition
databases, and diﬀerences in bioavailability. Future studies
maybeimprovedbybettertakingintoaccountbioavailability
diﬀerences among diverse foods. Prospective studies are pre-
ferable to avoid various biases, such as recall bias, or reverse
causation in studies of circulating lycopene. With increasing
use of PSA, it is becoming increasingly diﬃcult to examine
advanced stage prostate cancer, at least in some populations.
Examining potential mediators or markers of aggressive
behavior in tumor tissue may be another useful approach in
the further study of lycopene and prostate cancer risk.
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